Sirolimus Rx: compounding pharmacy vs research supplier

Last updated 2026-07-27

What's actually different between a compounding pharmacy and a research supplier?

A compounding pharmacy is a licensed facility, staffed by pharmacists, regulated by a state board of pharmacy and (for sterile or certain non-sterile prep) held to USP General Chapter <795> and <797> standards. It fills a prescription written by a physician or nurse practitioner after some kind of clinical review, however brief. The vial you get has a lot number, an expiration date tied to actual stability testing or USP beyond-use-date defaults, and a pharmacist's name attached to it. If something goes wrong, there's a license on the line and a state board that can be called. A research supplier sells sirolimus (or 'rapamycin') as a research chemical, no prescription required, often marketed with language like 'not for human consumption.' These companies aren't compounding pharmacies. They aren't inspected by a state board of pharmacy. Nobody is verifying sterility, potency, or purity against a pharmacopeial standard unless the buyer pays for independent third-party testing themselves, which almost nobody does. The FDA has warned repeatedly that medicines bought outside licensed, legitimate supply channels, including online sellers exploiting regulatory gray zones, carry real risk of contamination, mislabeling, or containing undeclared ingredients entirely ^[1]. The molecule can be identical on paper. Sirolimus is rapamycin, same compound, and that's not a marketing distinction, it's a chemistry fact confirmed in the FDA-approved Rapamune labeling itself ^[2]. What differs is everything around the molecule: who verified what's actually in the vial, who's legally accountable, and whether a clinician ever looked at your labs before you took it.

Is compounded sirolimus legal, and does that make it 'safe'?

Compounding is legal under a specific structure, not a free pass. Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) allows a licensed pharmacist to compound a drug for an individual patient based on a valid prescription, outside the FDA's new-drug approval process, as long as the pharmacy follows USP standards and isn't compounding copies of commercially available FDA-approved products ^[3]. Rapamune (oral sirolimus) is FDA-approved, so a compounding pharmacy generally isn't supposed to just remake tablets wholesale; what they're doing when they compound sirolimus for off-label longevity dosing is usually adjusting form or strength (a specific capsule dose, a specific concentration, sometimes a topical or non-oral prep) that isn't commercially sold that way, tied to your individual prescription. 'Legal' doesn't mean 'FDA-reviewed for this use.' The statute itself is explicit that section 503A compounding is exempted from the standard new-drug approval and labeling requirements, not evaluated under them ^[3]. The oversight is procedural: is the pharmacy licensed, is it following USP <795>/<797>, is there a real prescription. It's not a guarantee the specific longevity dosing regimen has been proven safe or effective, because that trial doesn't exist yet for humans, at any source. What you're buying with a compounding pharmacy is process integrity, not outcome proof. That's still worth a lot. Contamination, wrong concentration, and mislabeling are the actual near-term risks with any injectable or oral prep, and those are exactly what licensure and USP chapters are built to catch.

What does the human evidence actually say about rapamycin and lifespan?

There is no completed human trial showing rapamycin extends lifespan or healthspan. None. Full stop. This is the single fact every longevity-minded reader needs sitting at the top of their head before anything else in this article matters. The animal data is real and it's strong. The NIA Interventions Testing Program (ITP), running rapamycin trials across three sites since 2006, has repeatedly found that rapamycin extends median lifespan in genetically heterogeneous mice, on the order of 9-14% in females and somewhat less consistently in males depending on dose and start age, with effects also seen when treatment starts as late as 20 months of age ^[4]. This is one of the most replicated findings in mouse aging science, across multiple independent cohorts and dose levels. Mice are not humans. The extrapolation from 'extends lifespan in a mouse fed rapamycin for most of its adult life' to 'a 45-year-old taking a weekly compounded dose will live longer' is a hypothesis, not a finding. The closest human data is small, short trials on surrogate markers, like the 2014 Mannick et al. study in Science Translational Medicine showing rapalogs (a related drug, everolimus) improved immune response to influenza vaccine in elderly subjects over roughly 6 weeks ^[5]. That's immune function, not lifespan, and it's a different molecule in the rapalog family. There's no six-year, twenty-year, or even one-year randomized controlled trial of low-dose intermittent sirolimus and human mortality. Anyone selling you a version of this drug for longevity, compounded or research-grade, is selling you into that gap.

What are the real risks of off-label rapamycin dosing?

Sirolimus is FDA-approved as a systemic immunosuppressant, originally for kidney transplant rejection prophylaxis, and its full prescribing information carries a boxed warning about increased risk of infection and lymphoma from immunosuppression ^[2]. That's not a longevity-dosing footnote, that's the label for the approved drug at approved doses. The off-label 'intermittent' or 'pulsed' protocols people use for longevity (once-weekly low doses, for example) are an attempt to get mTOR inhibition benefits while minimizing continuous immunosuppression, based on the ITP's finding that intermittent dosing still extended mouse lifespan ^[4]. It's a reasonable-sounding theory. It has not been validated in a controlled human trial for safety or efficacy at any specific weekly dose. Real, documented side effects of sirolimus at therapeutic transplant doses include mouth ulcers (stomatitis), which is one of the most common adverse events reported in the Rapamune label ^[2], along with hyperlipidemia (elevated cholesterol and triglycerides), delayed wound healing, and increased infection risk from immune suppression. At the lower intermittent doses used off-label, anecdotal reports suggest milder versions of these, but nobody has run the dose-ranging safety study that would tell you the real incidence at, say, 5mg once weekly versus 6mg once weekly. Metabolic effects (blood glucose and lipid shifts) show up in transplant patients and are a reasonable thing to monitor with bloodwork if you're taking this off-label, regardless of where you sourced it.

Does a prescription actually change anything meaningful?

Yes, mostly around monitoring and dose logic, not around proving the longevity claim. A prescriber worth using should be checking baseline labs (lipid panel, CBC, kidney function, sometimes a trough sirolimus level) before and periodically during use, watching for the known side effect list, and adjusting or stopping if something looks off. A research supplier transaction has none of that. You place an order, a vial shows up, and nobody is watching your labs. A prescription also means someone with a license is putting their name on the decision that this specific dose, for this specific person, is a reasonable off-label trial. That's a real check, even though it's not the same as an FDA-reviewed indication. It's the difference between 'a clinician reviewed my situation and is tracking it' and 'I decided this myself based on a podcast and a spreadsheet.' What a prescription doesn't do is retroactively create the missing outcome trial. If your prescriber is enthusiastic but not asking for labs, not discussing infection risk, and not mentioning the mouse-to-human evidence gap, that's a red flag regardless of how official the paperwork looks.

How do quality controls actually differ, vial to vial?

Why would anyone still buy from a research supplier?

Mostly cost and access. Research suppliers don't require a doctor's visit, a prescription, or the markup that comes with pharmacy licensure and compliance overhead. For someone who can't find a prescriber willing to write off-label sirolimus, or who doesn't want the appointment and lab-monitoring hassle, the research route looks like the path of least resistance. It's also, frankly, a bet that the seller is honest and the compound is what the label says. Some research chemical vendors probably do sell accurately-labeled sirolimus. There's no independent, ongoing verification process that tells a buyer which vendors those are, and no recourse if it turns out wrong, since the product was never sold as a human drug in the first place. If cost is the real barrier, it's worth comparing against what a compounded prescription actually runs before assuming research-grade is the only affordable option. Compounded sirolimus for off-label longevity dosing commonly runs somewhere in the range of $1-3 per mg-equivalent dose depending on the pharmacy and formulation, though exact pricing varies by pharmacy and isn't standardized or published the way FDA-approved drug pricing sometimes is; get a direct quote rather than assuming.

What should a longevity researcher actually weigh here?

Separate two questions that get muddled constantly: 'is this sourcing route safe and legitimate' and 'does rapamycin extend human lifespan.' The compounding-versus-research-supplier question only answers the first one. Even a perfectly sourced, pharmacist-verified, prescription-backed vial of sirolimus is still an off-label bet on a drug whose human longevity data doesn't exist yet. If you're going to use it anyway, on the working theory that mouse data plus mechanistic plausibility (mTOR inhibition, autophagy induction) is a good enough reason to try it personally, then sourcing quality is a real and separate variable worth getting right. A compounding pharmacy with a prescription and lab monitoring reduces the near-term risks (wrong dose, contamination, no one watching for stomatitis or lipid problems). It does nothing to close the mouse-to-human evidence gap, and no marketing claim from any seller should be read as if it does. If you go the prescription route, get the dosing logic straight first. The Sirolimus Rx dosage guide and the Sirolimus Rx dosage calculator are the practical starting points before anything ships.

What does a provider-reviewed route actually look like in practice?

A provider-reviewed route means a licensed clinician reviews your history and labs, writes an actual prescription, and that prescription is filled by a licensed compounding pharmacy rather than shipped from an unregulated 'research chemical' storefront. Sirolimus Rx works this way: the clinical review happens first, and the fulfilling pharmacy partner compounds and dispenses under standard pharmacy licensure and USP oversight, not in-house at Sirolimus Rx itself. That structure doesn't change the underlying science. It doesn't produce a human lifespan trial that doesn't exist. What it does is put a licensed person on both ends of the transaction, the prescriber and the pharmacist, instead of neither. For a drug where dosing, injection technique, and monitoring genuinely matter, that's the difference between an informed off-label trial and a guess. If you're past the sourcing question and into logistics, the practical guides worth reading next cover how to reconstitute Sirolimus Rx, how to inject, injection sites, and cycle length.

Frequently asked questions

Is sirolimus the same thing as rapamycin?

Yes. Sirolimus is the generic drug name; rapamycin is the original compound name derived from Streptomyces hygroscopicus, found on Easter Island (Rapa Nui). They are chemically identical. The FDA-approved product Rapamune uses sirolimus as its active ingredient, confirmed in its official labeling.^[2]

Is buying rapamycin from a research chemical company illegal?

It's legally murky rather than clearly illegal for the seller, since these companies market products as 'not for human consumption' to avoid drug regulation. For the buyer, using it as a medication without a prescription sidesteps the licensed-pharmacy framework entirely and carries no quality or safety guarantee.^[1]

Has rapamycin been proven to extend human lifespan?

No. There is no completed human trial demonstrating rapamycin extends lifespan or healthspan. The strongest evidence is in mice, from the NIA Interventions Testing Program, which found consistent lifespan extension across multiple independent trial cohorts.^[4] Human data is limited to short studies on immune and metabolic markers, not mortality.

What is the NIA Interventions Testing Program?

It's a National Institute on Aging-funded program testing candidate lifespan-extension compounds simultaneously across three research sites (University of Michigan, Jackson Laboratory, University of Texas Health Science Center) in genetically diverse mice, to ensure results replicate before being taken seriously.^[4] Rapamycin is its most consistently replicated finding to date.

What side effects does sirolimus actually cause?

At FDA-approved transplant doses, documented effects include mouth ulcers (stomatitis), elevated cholesterol and triglycerides, increased infection risk, and impaired wound healing, all listed in the official prescribing information along with a boxed warning about infection and malignancy risk from immunosuppression.^[2] Lower off-label doses may reduce severity but haven't been formally studied.

Does a compounding pharmacy make sirolimus safer than a research supplier?

It improves process safety: licensed oversight, USP <795>/<797> standards, prescription requirements, and lot tracking reduce contamination, mislabeling, and dosing errors.^[6] It does not prove the off-label longevity use itself is safe or effective long-term, since that outcome data doesn't exist for either sourcing route.

What is USP <795> and <797>, and why does it matter for compounded sirolimus?

These are United States Pharmacopeia chapters setting standards for non-sterile (<795>) and sterile (<797>) pharmaceutical compounding, covering facility conditions, testing, and beyond-use dating. Pharmacies compounding sirolimus preparations are expected to follow whichever chapter applies to the dosage form.^[6]

Can a doctor legally prescribe sirolimus for longevity even though it's off-label?

Yes. Once a drug is FDA-approved for any indication, physicians can generally prescribe it off-label based on clinical judgment. What's not permitted is a manufacturer marketing it for an unapproved use. A prescriber writing off-label sirolimus for aging-related purposes is operating within accepted, if unproven, medical practice.

How much does compounded sirolimus typically cost versus research-grade product?

Compounded sirolimus for off-label dosing commonly runs in a range of roughly $1-3 per mg-equivalent dose depending on the pharmacy, though pricing isn't standardized or published broadly. Research suppliers are often cheaper per unit but carry no verified purity, potency, or sterility standard, so the price comparison isn't apples to apples.

What's the difference between sirolimus and rapalogs like everolimus?

Rapalogs are chemically modified derivatives of rapamycin (everolimus is one example) designed to alter pharmacokinetics. They're related mTOR inhibitors but not identical molecules. Some human immune-function studies, like Mannick et al. 2014, used everolimus-based rapalogs, not sirolimus itself, so results don't directly transfer.^[5]

Why do people use intermittent or weekly dosing instead of daily sirolimus?

The theory, based on ITP mouse data showing intermittent dosing still extended lifespan, is that pulsed dosing might capture mTOR-inhibition benefits while reducing continuous immunosuppression and side effects like infection risk.^[4] This specific dosing strategy has not been validated in controlled human trials for safety or efficacy.

What lab monitoring should someone on off-label sirolimus expect?

A reasonable protocol includes baseline and periodic lipid panel, complete blood count, kidney function tests, and sometimes a sirolimus trough blood level, watching for the known effects seen in transplant patients: elevated lipids, low blood counts, and infection signs. A prescriber should be the one ordering and interpreting these, not a self-managed guess.

Is Fyarro or Hyftor the same drug as generic sirolimus?

Same active molecule, different approved formulations and indications. Fyarro (sirolimus protein-bound particles) is approved for a rare soft tissue sarcoma (PEComa), and Hyftor is a topical sirolimus gel approved for facial angiofibromas in tuberous sclerosis complex. Neither is approved for longevity use.

Sources

1. U.S. Food and Drug Administration, Consumer Update: The Danger of Buying Medicines from Unlicensed Online Pharmacies: FDA guidance warning that products sold outside licensed, approved drug channels carry risk of contamination, mislabeling, or wrong ingredients entirely
2. FDA-approved label, Rapamune (sirolimus) prescribing information, NDA 021083: Sirolimus is the active ingredient in Rapamune; boxed warning on infection/malignancy risk; stomatitis and hyperlipidemia listed as adverse effects
3. 21 U.S.C. 353a, Federal Food, Drug, and Cosmetic Act, Section 503A (Pharmacy Compounding): Legal framework under Section 503A allowing pharmacy compounding for individual patients based on a valid prescription, exempt from standard new-drug approval and labeling requirements
4. National Institute on Aging, Interventions Testing Program: NIA ITP findings that rapamycin extends median lifespan in genetically heterogeneous mice across multiple independent test sites, including when started later in life
5. Mannick et al., Science Translational Medicine, 2014, PMID 25540326: RAD001 (everolimus, a rapalog) improved influenza vaccine response in elderly subjects in a short human trial
6. United States Pharmacopeia, General Chapter <797> Pharmaceutical Compounding, Sterile Preparations: USP standards governing non-sterile and sterile pharmaceutical compounding facility, testing, and beyond-use dating requirements